secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0000950170-24-094359
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma Q1 FY2025 net loss $2.6M; STRIVE-ON trial enrollment exceeds 50%
------------------------------------------------------------------------------

- Net loss of $2.6M ($0.24 loss per share) vs $4.0M ($0.54) in prior-year quarter.
- Cash and equivalents $19.4M as of June 30, 2024; projected runway into Q2 2026.
- Pivotal Phase 3 STRIVE-ON safety trial surpassed 50% enrollment; completion expected late 2024 to early 2025.
- NDA submission to FDA for GTX-104 anticipated in first half of calendar 2025.
- R&D expenses rose to $2.7M from $1.1M, driven by GTX-104 clinical activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024094359/0000950170-24-094359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024094359/acst-20240809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-094359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer